Effectiveness of netakimab in psoriasis and psoriatic arthritis with concomitant metabolic syndrome
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Psoriasis and psoriatic arthritis are characterized by a high prevalence, a chronic progressive course, the frequent presence of severe forms, comorbidities, and a significant decrease in patients’ quality of life, which justifies high demands on the efficacy and safety of therapy for these diseases. The article describes two clinical cases of the successful use of the interleukin 17 (IL-17) inhibitor netakimab in patients with psoriasis and psoriatic arthritis with concomitant metabolic syndrome. Netakimab was administered at a dose of 120 mg as subcutaneous injections once weekly on weeks 0, 1, and 2, followed by 120 mg once every 4 weeks. The treatment efficacy was assessed by clinical and laboratory examination using PASI, DAS28, and NAPSI scores. Netakimab treatment resulted in regression of subjective and objective skin symptoms and sustained clinical and laboratory remission of joint syndrome. Netakimab treatment was free of adverse events and significantly improved patients’ quality of life.
Fields of Study & Subjects
Psoriasis: Treatment and Pathogenesis
Spondyloarthritis Studies and Treatments
Dermatology and Skin Diseases
Publication details
- Journal / source
- Vestnik dermatologii i venerologii
- Volume
- 102
- Issue
- 1
- Pages
- 68–75
- Publication date
- 28 March 2026
- Language
- EN